Inform Genomics Inc.
Predicting side effects of specific drug regimens
This article was originally published in Start Up
While other personalized medicine companies tend to focus on selecting the most effective therapeutic drug, say for cancer, Inform Genomics Inc.’s focus with its lead product is to identify patients who have a genetic predisposition to specific side effects from cancer treatments. The company is looking across vast networks of genes to pinpoint characteristics that spell trouble for a patient. Each genetic profile is unique to the risks associated with a specific drug regimen: a patient’s profile may raise a red flag for severe side effects associated with one regimen, but may show that another regimen may be relatively safe.
You may also be interested in...
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.